Investment Committees


Uniseed has two Investment Committees – one for Biotechnology (Bio) and the other for Deep Technology (Tech).  The Uniseed investment team members serve on both committees and are supported by a number of specialist managers.

Peter Devine


Peter Devine became CEO of Uniseed in 2006, transitioning from his initial role as Uniseed Investment Director.  Peter has extensive experience at board and executive management levels in the commercialisation of early stage technologies, having held senior R&D, business development and commercialisation positions in a number of Australian companies and Australian universities.  Before joining Uniseed, Peter was Vice President of Business Development at Progen Industries Ltd.  He was Research, Development and Commercialisation Manager at Brisbane-based PanBio Pty Ltd from 1996 to 2000 and also worked in business development at UniQuest Pty Ltd.

Peter holds a PhD from the University of Queensland and received the Dean’s Prize for his MBA Studies at the Australian Graduate School of Management.  He received a Centenary Medal in 2003 for outstanding contribution to the business of biotechnology.  He is a Graduate and Fellow of the Australian Institute of Company Directors and holds Diploma of Financial Services (Financial Markets) and a Graduate Diploma in Applied Finance from Kaplan Professional. In 2011 & 2012, Peter was named on the Kaplan High Achievers Honour Roll.

Natasha Rawlings

Investment Manager, Sydney

Natasha Rawlings has joined Uniseed as an Investment Manager in Sydney.  Natasha is a tech entrepreneur who has led, founded and mentored early and mid-stage tech start-ups, with a particular focus on creating revenue through sales and marketing. Prior to this, Natasha had a successful career as a marketer holding top management positions in Australian and UK companies.

Natasha brings her strong commercial acumen to the Uniseed team, where she has rich experience in new product development and building revenues through new routes to market. Natasha’s previous roles include CEO and Founder of StreetHawk, a mobile relationship management platform, and CEO of Heads Over Heels – an organisation that helps women entrepreneurs with scalable businesses grow.

Natasha’s corporate experience includes Marketing Director of International Masters Publishers (publishing) and Guthy-Renker (cosmetics and fitness), and as a Senior Manager in corporate innovation and new revenue streams at News Corporation in the UK.

Natasha holds a Bachelor of Business from the University of Technology, Sydney.

John Kurek

Investment Manager, Melbourne

John joined Uniseed as an Investment Manager in Melbourne. He is responsible for working closely with Melbourne Ventures Limited, the University of Melbourne’s commercialisation group, in identifying new investment opportunities, and also covers Uniseed’s overall biotechnology opportunities.

John brings extensive industry experience as a Biotechnology Manager with a focus on the strategic design and implementation of drug development programs. John’s previous roles have included Pharmaceutical Development Manager at BioDiem Ltd, where he was responsible for managing the preclinical, clinical and regulatory aspects of BioDiem’s drug development programs, and Preclinical Development Manager at Amrad Corporation Ltd where he was responsible for the management of preclinical drug development projects. His experience extends from drug discovery, to the phase I-II clinical phases of drug development. John has a PhD in Neuroscience and a Post Graduate Diploma in Drug Evaluation and Pharmaceutical Science, both from the University of Melbourne and is a Graduate of the Australian Institute of Company Directors.

Anthony Musumeci

Investment Manager, Brisbane

Anthony Musumeci is Uniseed’s Investment Manager located at UQ. Anthony was formerly Innovation Investment Manager at boutique investment fund Black Sheep Capital in Brisbane, where he was responsible for management of the Black Sheep Capital early stage innovation investment portfolio, which includes; identification new investment opportunities, due diligence processes, investment negotiation and growing the Black Sheep investment networks and relationships. Prior to that, Anthony worked as a Commercial Manager and Technology Commercialisation Analyst at two technology transfer offices – BlueBox at QUT and UniQuest at UQ.

Over the last 10 years Anthony has worked with a wide range of new innovations predominantly in the science, engineering and information technology fields. Anthony has experience in commercialisation strategy, intellectual property, technology licensing, grant and capital raising from these roles. Anthony holds a Bachelor of Applied Science (Hons) – Chemistry, and Executive MBA and a PhD in materials science/chemistry. He also has a Graduate Certificate in Research Commercialisation.

Kathryn Sunn    (Bio)

Commercialisation Manager, Commercial Development & Industry Partnerships, University of Sydney

Kathryn is a highly motivated Intellectual Property and Commercialisation Professional with a unique value proposition that combines commercial acumen with broad technical expertise, and a passionate focus on strategic growth and technology collaborations in the Medical and Life Sciences commercial arena.

With over 16 year’s experience in Intellectual Property, IP strategy, commercialisation and business development comprised from roles in two of Australia’s top tier Patent firms and the University of Sydney ; she has established a track record in maximising impact from strategic collaborations and partnerships, and in providing commercially focused advice to leverage innovations into valuable assets.

Prior to industry participation she enjoyed a productive career as a medical researcher working in one of Australia’s leading medical research organisations.

Joy Francisco   (Bio) On Maternity Leave

Business Development Manager, Life Sciences Knowledge Exchange, Division of Enterprise, UNSW

Joy is a registered technology transfer professional with a PhD and MBA. Joy has worked in the technology transfer offices of the US National Institutes of Health, Massachusetts Institute of Technology (MIT), the University of Melbourne and UNSW.  US and Australian experience in intellectual property (IP) and commercialisation strategy, licensing of early-stage technologies, commercial contract negotiation, and business development. Managed multidisciplinary IP/technology portfolios spanning healthtech, medtech, biotech, pharmaceuticals, materials, cleantech, software and digital technologies.

Madeline Yap     (Bio)

Business Development and Commercialisation, CSIRO

Madeline brings over 20 years of experience in the biomedical and life sciences sector. She has extensive experience in operations management and research commercialisation, including the identification of innovative commercialisation opportunities, development of business plans and strategic collaborations, cross-cultural business and negotiations, business development, startups, clinical trials and medical communications & marketing.

Madeline has previously served in senior management, partner and consulting roles in Asia for many years and has worked in industry at large multinational companies with Fortune500 clients, as well as at innovative and renowned public research universities in Australia and abroad. She is currently part of the CSIRO Commercialisation Team and is based in Sydney.

Madeline holds a PhD (Medicine) from the University of Sydney and has management credentials from the Macquarie Graduate School of Management. Besides English, she is also fluent in Cantonese and Mandarin.

Katrina Sorocos (Bio)

Senior Technology Transfer and Licensing Officer, RIC, University of Melbourne

Katrina has over 9 years experience in commercialisation of early stage technologies within both the University and Investment sectors. Katrina leads the Life Sciences Portfolio within the IP & Technology Transfer team in RIC at the University of Melbourne and is involved in assessing, protecting and developing University technologies as well as identifying and negotiating with commercial partners or investors to further develop and exploit these technologies.

Previously, Katrina held Business Development roles within the Faculty of Medicine, Nursing and Health Sciences at Monash University and was involved in commercialising University technologies as well as identifying and facilitating a range of research funding and development opportunities with government and industry partners. Katrina also held an Investment Analyst role with the Trans-Tasman Commercialisation Fund, working closely with Investment Managers on sourcing and building investment proposals and performing due diligence on investment opportunities in early stage University technologies.

Katrina has completed a Bachelor of Biotechnology with First Class Honours and Master of Business (Science & Technology) at Monash University.

Ross Macdonald (Bio)

Chief Executive Officer & Managing Director at Cynata Therapeutics (Independent Committee Member)

Ross Macdonald is Chief Executive Office and Managing Director at ASX-listed Cynata Therapeutics.  Ross has an extensive and successful background in the pharmaceutical industry.  With eighteen years local and international experience in unit and general management in the industry, he has brought several products from lab bench to market.  Ross also has broad-based experience in profit centre management, technology commercialisation, strategic planning, deal negotiation and transaction (licensing, M&A, asset sale & purchase), market and industry analysis, human resource management, product development and finance. Ross was Vice President, Business Development at Sinclair Pharmaceuticals Ltd, a UK based speciality pharmaceuticals company.  Prior to joining Sinclair Pharmaceuticals Ltd, he was Vice President, Corporate Development for Stiefel Laboratories, Inc, (Coral Gables, FL, now part of GlaxoSmithKline), Vice President of Business Development for Connetics Corporation (Palo Alto, CA), Vice President of Research & Development with F.H. Faulding & Co Limited (now part of Mayne Group/Hospira Inc) and Managing Director of Soltech Research.

Ross has a PhD in Biochemistry from Monash University and a Graduate Diploma in Business Administration from Swinburne University.

Ben Phillis         (Bio)

Director, Asset Management, UniQuest

Ben leads medical technology development in devices and drug delivery for UniQuest Pty Ltd, the main commercialisation company of The University of Queensland. His role is concerned with identifying, validating, protecting, developing and executing commercialisation plans for new technologies. Ben has more than 10-years’ experience in innovation management, technology development & commercialisation. Prior to UniQuest, Ben worked in a number of roles for Mayne Pharma in innovation and business development and has experience in pharmaceutics, modified release formulations and pharmaceutical product life-cycle management.

Ben has a basic research background in experimental pharmacology and toxicology and holds a Ph.D. from The University of Adelaide. His dissertation was concerned with cardiotoxicity associated with anabolic steroids. He completed a post-doctoral fellowship in neuropharmacology at the Hanson Institute working on an industry funded drug discovery program.

Ben is a member of the local organising committee of the Licensing Executives Society (LES) and an active member of AusBiotech.

Leong Mar       (Tech)

Commercialisation Manager, Business Development and Commercial, CSIRO

At CSIRO, Leong manages the commercialisation of technologies developed by a number of the business units and provides mentoring for potential spin-out teams on their entrepreneurial journey. Prior to CSIRO, Leong spent 10 years with DuPont where he held and number of roles including managing the ANZ Technical Centre, leading Corporate Business Growth and Innovation. During this time he led the development of multi award winning product and service solutions for the mining industry and helped identify and commercialise a number of new product offerings in different industries.

Leong is an experienced Technologist, Innovator and Entrepreneur with a unique combination of commercial and technical leadership experience gained over 20 years from working in spectrum of organisations including tech start-ups, small business, research organisations and one of the world’s iconic science corporations. With an expansive knowledge and expertise across the physical and chemical sciences Leong has a successful track record in identifying, developing and commercialising products and services in different industries.

Leong has a BSc(Hons) and PhD in Chemistry from UNSW, is a Graduate of the Australian Institute of Company Directors and Six Sigma Green Belt qualified.

Michael Angliss (Tech)

Chief Intellectual Property Officer Director, Commercial Engagement - Science, UniQuest

Michael is Chief Intellectual Property Officer and Director, Commercial Engagement at UniQuest.  In addition to the responsibility for leading the strategy and management of intellectual property developed at The University of Queensland, Michael leads commercialisation of projects across numerous application areas within the disciplines of materials, chemistry and physics.  He also sits on the boards of ProGel Pty Ltd, PERKii Pty Ltd and SMART Arm Pty Ltd.

Michael has more than 30 years’ experience in intellectual property and technology commercialisation. He started his career with ICI Australia Operations (now Orica) as a patents and licensing officer, responsible for the protection of in-house innovations, licensing of ICI technology and the in-licensing of third party technology. During the time at ICI, he was responsible for IP across a number of business units, including Advanced Ceramics, Explosives, Water Treatment, Plastics and Polymers and Industrial Chemicals.  Michael then spent a decade in private practice as a patent attorney in Melbourne and Brisbane, ultimately as a partner with Cullens.

Michael has a BSc, majoring in Materials Science and Chemistry from Monash University.  He is a Registered Patents and Trade Marks Attorney and a Fellow of the Institute of Patent and Trade Mark Attorneys of Australia (former committee member).  He is a graduate of the Australian Institute of Company Directors.

Andrew Rudge (Tech)

Senior Business Development Manager, RIC, University of Melbourne

Dr Andrew Rudge joined UoM Commercial Ltd in 2012 and leads the technology commercialisation team focusing on Engineering, ICT and Physical Sciences. He has over 7 years of experience in commercialisation of innovative technologies and driving innovative businesses and product development teams for leading corporate investors and Universities.

Having worked at several Universities and venture capital backed technology companies, Andrew has a strong commercial and engineering background. In a previous role he was CEO of a start-up company built on optical detection technology developed at the University of Canterbury, and developed a client and distribution base across the United States, Asia and Europe.

Andrew completed his PhD in the Bioengineering Centre at the University of Canterbury and holds a Bachelor’s degree in Mechanical Engineering with first class Honours.

Andrew Tindell (Tech)

Director, Commercial Development & Industry Partnerships, University of Sydney

Andrew studied Chemistry at Oxford University and was awarded a DPhil in Physical Chemistry from Oxford University in 1982.

Andrew has over 30 years of experience in IT and telecommunications working in the Defence, Space, Telecommunications, Energy and Utilities sectors. During his time running Logica UK Limited’s Space business he was responsible for the team developing the on board software for the Huygens spacecraft that successfully landed on Titan a moon of Saturn on 14 January 2005. From 1997 to 2003 he was CEO of Logica Pty Ltd in Sydney, the Australian Subsidiary of the UK FT100 publicly listed company. During this time he was involved in several mergers and acquisitions which took the company from just over a 100 to over 750 staff.  Following this Andrew was Managing Director, Services for Cable and Wireless UK Limited in the UK.  On his return to Australia in 2006 Andrew has provided Management Consultancy and Coaching to small businesses and start ups.

Andrew started working at The University of Sydney in 2013, initially as Relieving Director for Research, Grants and Contracts and became Director Commercial Developments and Industrial Partnerships in March 2014.

He has extensive Operations, Business Development and Contract negotiation experience.

Dax Kukulj      (Tech)

Executive Manager, Business Development & Commercialisation Knowledge Exchange, Division of Enterprise, UNSW

Dax leads Business Development and Commercialisation in the Knowledge Exchange team at UNSW.  He has over 15 years’ experience developing and commercialising new technologies in start-ups, university and corporate research environments.  His technology experience covers advanced materials and high-tech sector including: robotics, devices, photonics, materials and data analytics. He has an MBA from AGSM and PhD in Polymer Materials and BSc in Industrial Chemistry from UNSW.  He is the author of 25 scientific articles, two book chapters, numerous conference presentations and has filed over 30 patent families.

Qiao Qiao           (Bio)

Business Development Manager Therapeutics, Knowledge Exchange, Division of Enterprise, UNSW

Qiao is an entrepreneurial life science business development professional. He is part of the Life Sciences team in Knowledge Exchange (KE). He also works closely with the UNSW Torch team and travels frequently to China to explore partnership opportunities. Qiao is dedicated to building long-lasting high value cooperation with biotechnology and pharmaceutical companies, sophisticated equity investors and other external partners. He has experience in a broad field, such as cancer, virology, biochemistry, stem cell biology. Prior to joining KE, Qiao worked at NewSouth Innovations (NSi), UNSW Torch (Life Sciences) as well as at Bio-Link Australia, a boutique life sciences consulting company. Qiao completed his PhD (Medicine) at UNSW and was awarded BSc (Biotech) with first class honours from the University of Adelaide.